The application scope of immunotherapy has gradually expanded from advanced non-small cell lung cancer to the perioperative stage, with three core clinical application forms progressively established: neoadjuvant therapy, adjuvant therapy, and comprehensive management combining neoadjuvant and adjuvant approaches. Recent clinical studies have demonstrated that all three treatment modalities can achieve improvements in pathological response and event-free survival. However, consensus remains elusive regarding the characteristics of beneficiary populations, efficacy differences among various treatment strategies, and perioperative-specific safety risks. By integrating recent clinical research findings and systematically reviewing evidence-based data for each therapeutic approach, this review aims to provide evidence-based support for rational clinical treatment selection.
Wang C, Yue D, Chen C, 2022, Advances in Immunotherapy for Perioperative Non-Small Cell Lung Cancer in 2022. China Oncology Clinical, 49(23): 1236–1241.
Hong W, Liao X, Cai R, et al., 2024, Latest Advances in Perioperative Immunotherapy for Non-Small Cell Lung Cancer. Journal of Nanchang University (Medical Edition), 64(2): 88–94.
Fang Y, Su C, 2025, Research Progress in Immunotherapy for Non-Small Cell Lung Cancer in 2024. Electronic Journal of Comprehensive Oncology Treatment, 11(1): 44–49.
Hao Z, Yun D, Zhang Y, et al., 2024, Research Progress on Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Advances in Neoadjuvant Immunotherapy. Journal of Capital Medical University, 45(4): 666–677.
Xu Y, Mao F, Chen X, et al., 2026, Research Progress on Perioperative Immunotherapy for Non-Small Cell Lung Cancer. China Journal of Cardiothoracic Surgery, 33(2): 318–325.
Xie Q, Nian W, Zhang Y, 2022, Expert Discussion on Clinical Decision-Making for Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Chongqing Medical Journal, 51(6): 901–909.
Liu X, Zhang G, Huang Y, et al., 2025, Hot Topics and Research Progress in Perioperative Immunotherapy for Non-Small Cell Lung Cancer. Journal of Clinical Surgery, 33(9): 938–942.
Wang C, Dai X, Xu S, et al., 2025, Clinical Research Status and Progress of Perioperative Immunotherapy for Early Resectable Non-Small Cell Lung Cancer. Chinese Journal of Cancer Prevention and Treatment, 32(15): 943–949, 960.
Ni J, Huang M, Zhang L, et al., 2021, Clinical Diagnosis and Treatment Recommendations for Adverse Reactions Related to Perioperative Immunotherapy in Non-Small Cell Lung Cancer. China Lung Cancer Journal, 24(3): 141–160.